Fennec holder Southpoint reports 8% ownership stake
Fennec Pharmaceuticals Inc. received an updated ownership filing showing that investment entities affiliated with Southpoint report beneficial ownership of 2,744,741 Common Shares, representing 8.0% of the company.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Fennec Pharmaceuticals Inc. received an updated ownership filing showing that investment entities affiliated with Southpoint report beneficial ownership of 2,744,741 Common Shares, representing 8.0% of the company. These shares are held by Southpoint Master Fund, LP, with related management and general partner entities, and by John S. Clark II in his capacities with those entities.
The reported ownership percentage is based on 34,153,496 outstanding Common Shares, as disclosed in a Prospectus Supplement filed on November 18, 2025. The reporting parties state that each of them disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What percentage of Fennec Pharmaceuticals (FENC) does Southpoint report owning?
Which entities filed this Schedule 13G/A for Fennec Pharmaceuticals (FENC)?
How was the 8.0% ownership in Fennec (FENC) calculated?
Do the Southpoint entities and John S. Clark II claim full beneficial ownership of their Fennec (FENC) shares?
Who ultimately signs the Fennec (FENC) Schedule 13G/A for the Southpoint group?
AI-generated analysis. How Rhea-AI works. Not financial advice.